fluoxetine has been researched along with Benign Neoplasms in 22 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer." | 8.81 | Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001) |
| "To observe the depression in patients with malignant tumor and influencing factors of the disease, as well as to investigate the effects of fluoxetine on depressive symptoms in cancer patients and the immune function." | 7.85 | Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine. ( Dai, J; Liao, N; Shi, J; Tao, JQ, 2017) |
| "Helping oncologists to identify and treat depression is an important step in improving the overall care of people with cancer." | 5.31 | Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. ( Donaghy, K; Dugan, W; Edgerton, S; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, D, 2002) |
| "To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey." | 5.10 | Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. ( Arquette, MA; Brames, MJ; Einhorn, LH; Fisch, MJ; Jung, SH; Kristeller, J; Loehrer, PJ; Passik, S; Shen, J, 2003) |
| "Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer." | 4.81 | Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001) |
| "To observe the depression in patients with malignant tumor and influencing factors of the disease, as well as to investigate the effects of fluoxetine on depressive symptoms in cancer patients and the immune function." | 3.85 | Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine. ( Dai, J; Liao, N; Shi, J; Tao, JQ, 2017) |
| "Of 115 cancer patients who fulfilled entry criteria for levels of distress, 45 patients were randomized to a fluoxetine treatment group (FA) and 46 patients to a placebo group (PA) after a 1-week placebo period designed to exclude placebo responders." | 2.68 | The effect of fluoxetine on anxiety and depression symptoms in cancer patients. ( Allilaire, JF; Blin, P; Bouhassira, M; Cordier, B; Desclaux, B; Fresco, R; Gauvain-Piquard, A; Guillibert, E; Mesters, P; Orth, JP; Piollet, I; Razavi, D; Salimpour, A; Saltel, P; Sechter, D; Smith, M; Trichard, C; Verra, M, 1996) |
| "Thus, one way to view cancer is within systems biology as a network disorder affecting the ability of cells to properly interact with a morphodynamic field of instructive signals that keeps proliferation and migration orchestrated toward the anatomical needs of the host organism." | 2.55 | Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer. ( Levin, M; Tilli, TM; Tuszynski, J, 2017) |
| "The possible anticancer activity of combination (M + E + F) of metformin (M), efavirenz (E), and fluoxetine (F) was investigated in normal HDF cells and HCT116 human colon cancer cells." | 1.91 | Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification. ( Feng, JH; Inci, G; Jung, JS; Kang, BG; Kim, JH; Kim, SB; Kim, SC; Lee, JY; Lim, SS; Mo, YW; Park, SH; Seo, JH; Shende, M; Suh, HW, 2023) |
| "Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters." | 1.34 | Does trazodone have a role in palliating symptoms? ( Davis, MP, 2007) |
| "Helping oncologists to identify and treat depression is an important step in improving the overall care of people with cancer." | 1.31 | Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. ( Donaghy, K; Dugan, W; Edgerton, S; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, D, 2002) |
| "Fluoxetine (Prozac) is an effective and increasingly widely used antidepressant." | 1.29 | Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. ( Koriech, OM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (36.36) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 2 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Kang, BG | 1 |
| Shende, M | 1 |
| Inci, G | 1 |
| Park, SH | 1 |
| Jung, JS | 1 |
| Kim, SB | 1 |
| Kim, JH | 1 |
| Mo, YW | 1 |
| Feng, JH | 1 |
| Kim, SC | 1 |
| Lim, SS | 1 |
| Suh, HW | 1 |
| Lee, JY | 1 |
| He, S | 1 |
| Moutaoufik, MT | 1 |
| Islam, S | 1 |
| Persad, A | 1 |
| Wu, A | 1 |
| Aly, KA | 1 |
| Fonge, H | 1 |
| Babu, M | 1 |
| Cayabyab, FS | 1 |
| Tuszynski, J | 1 |
| Tilli, TM | 1 |
| Levin, M | 1 |
| Dai, J | 1 |
| Liao, N | 1 |
| Shi, J | 1 |
| Tao, JQ | 1 |
| Zhu, L | 1 |
| Ploessl, K | 1 |
| Kung, HF | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Passik, SD | 1 |
| Kirsh, KL | 1 |
| Theobald, D | 1 |
| Donaghy, K | 1 |
| Holtsclaw, E | 1 |
| Edgerton, S | 1 |
| Dugan, W | 1 |
| Fisch, MJ | 1 |
| Loehrer, PJ | 1 |
| Kristeller, J | 1 |
| Passik, S | 1 |
| Jung, SH | 1 |
| Shen, J | 1 |
| Arquette, MA | 1 |
| Brames, MJ | 1 |
| Einhorn, LH | 1 |
| Alliot, C | 1 |
| Coyne, JC | 1 |
| Palmer, SC | 1 |
| Shapiro, PJ | 1 |
| Davis, MP | 1 |
| Mathews, J | 1 |
| Pande, AC | 1 |
| Miller, LG | 1 |
| Koriech, OM | 1 |
| Storch, DD | 1 |
| Razavi, D | 1 |
| Allilaire, JF | 1 |
| Smith, M | 1 |
| Salimpour, A | 1 |
| Verra, M | 1 |
| Desclaux, B | 1 |
| Saltel, P | 1 |
| Piollet, I | 1 |
| Gauvain-Piquard, A | 1 |
| Trichard, C | 1 |
| Cordier, B | 1 |
| Fresco, R | 1 |
| Guillibert, E | 1 |
| Sechter, D | 1 |
| Orth, JP | 1 |
| Bouhassira, M | 1 |
| Mesters, P | 1 |
| Blin, P | 1 |
| Henney, JE | 1 |
| Cheer, SM | 1 |
| Goa, KL | 1 |
| Shuster, JL | 1 |
| Stern, TA | 1 |
| Greenberg, DB | 1 |
| Viswanathan, R | 1 |
| Paradis, C | 1 |
5 reviews available for fluoxetine and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinogenesis; Cell Movement; Cell Proliferation; | 2020 |
Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer.
Topics: Animals; Antineoplastic Agents; Bioelectric Energy Sources; Cell Proliferation; Cell Survival; Fluox | 2017 |
Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.
Topics: Acquired Immunodeficiency Syndrome; Antidepressive Agents; Clinical Trials as Topic; Cytochrome P-45 | 2001 |
Pros and cons of fluoxetine for the depressed cancer patient.
Topics: Antidepressive Agents; Depression; Fluoxetine; Half-Life; Humans; Neoplasms | 1992 |
2 trials available for fluoxetine and Benign Neoplasms
| Article | Year |
|---|---|
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; | 2003 |
The effect of fluoxetine on anxiety and depression symptoms in cancer patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Doubl | 1996 |
15 other studies available for fluoxetine and Benign Neoplasms
| Article | Year |
|---|---|
Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Fluoxetine; HCT116 Cells; Human | 2023 |
Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Killer Cells | 2017 |
Chemistry. Expanding the scope of fluorine tags for PET imaging.
Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioi | 2013 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Male; | 2002 |
Fluoxetine versus placebo in advanced cancer outpatients.
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2004 |
Prescribing antidepressants to advanced cancer patients with mild depressive symptoms is not justified.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; | 2004 |
Does trazodone have a role in palliating symptoms?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2007 |
Concern over Prozac-induced tumor growth may dwindle following FDA study.
Topics: Amitriptyline; Animals; Depression; Fluoxetine; Humans; Loratadine; Neoplasms; Recurrence; United St | 1995 |
Response to "Antidepressants and cancer: cause for concern?".
Topics: Animals; Fluoxetine; Humans; Mice; Neoplasms; Rats | 1993 |
Antidepressants and cancer: cause for concern?
Topics: Amitriptyline; Animals; Antidepressive Agents; Cocarcinogenesis; Depressive Disorder; Fluoxetine; Hu | 1993 |
Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients.
Topics: Adult; Antiemetics; Binding, Competitive; Female; Fluoxetine; Humans; Male; Middle Aged; Neoplasms; | 1995 |
Do antidepressants promote tumor growth?
Topics: Animals; Antidepressive Agents; Carcinogens; Depressive Disorder; Fluoxetine; Humans; Neoplasms; Sel | 1996 |
From the Food and Drug Administration.
Topics: Administration, Oral; Antiviral Agents; Cyclosporine; Drug and Narcotic Control; Drug Labeling; Fluo | 2000 |
Treatment of cancer phobia with fluoxetine.
Topics: Adult; Female; Fluoxetine; Humans; Hypochondriasis; Neoplasms; Obsessive-Compulsive Disorder | 1991 |